FLT3 and acute myeloid leukemia: While response rates with HMA/LDAC + venetoclax are similar in patients with FLT3-mutated and FLT3 wild type AML, the clonal expansion of FLT3-mutated cells in response to these therapies suggest that these mutations are an important mechanism of relapse.